X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7) 7
female (5) 5
breast cancer (4) 4
care and treatment (4) 4
index medicus (4) 4
male (4) 4
oncology (4) 4
cancer (3) 3
dermatology (3) 3
melanoma (3) 3
metastasis (3) 3
multicenter (3) 3
mutation (3) 3
research (3) 3
aged (2) 2
antineoplastic agents - therapeutic use (2) 2
biomarkers (2) 2
biomarkers, tumor - blood (2) 2
breast neoplasms - pathology (2) 2
case report (2) 2
chemotherapy (2) 2
fluorodeoxyglucose f18 (2) 2
kinases (2) 2
melanoma - drug therapy (2) 2
melanoma - pathology (2) 2
metabolism (2) 2
middle aged (2) 2
oncology, experimental (2) 2
patient outcomes (2) 2
patients (2) 2
physiological aspects (2) 2
positron-emission tomography (2) 2
proteins (2) 2
reference standards (2) 2
survival (2) 2
therapy (2) 2
tumors (2) 2
1-phosphatidylinositol 3-kinase (1) 1
5-s-cysteinyldopa (1) 1
adult (1) 1
adverse drug reaction (1) 1
aged, 80 and over (1) 1
alternative therapy (1) 1
analysis (1) 1
angiogenesis (1) 1
angiogenesis inhibitors (1) 1
animals (1) 1
anthracycline (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - adverse effects (1) 1
arzneimittelresistenz (1) 1
atypical melanoma (1) 1
atypical presentation (1) 1
biopsy (1) 1
bone metastases (1) 1
bone neoplasms - diagnosis (1) 1
bone neoplasms - diagnostic imaging (1) 1
bone neoplasms - secondary (1) 1
braf inhibitor (1) 1
brain neoplasms - drug therapy (1) 1
brain neoplasms - secondary (1) 1
breast neoplasms - drug therapy (1) 1
calibration (1) 1
cancer patients (1) 1
cancer therapies (1) 1
capecitabine (1) 1
carrier proteins - chemistry (1) 1
carrier proteins - metabolism (1) 1
cell line, tumor (1) 1
cell survival (1) 1
cells (1) 1
chemical compounds (1) 1
chemistry, analytical (1) 1
chromatography, liquid - methods (1) 1
clinical trials (1) 1
clinical trials as topic (1) 1
codon (1) 1
codon - drug effects (1) 1
codon - genetics (1) 1
complications (1) 1
cysteinyldopa - blood (1) 1
cytotoxicity (1) 1
dabrafenib (1) 1
dacarbazine (1) 1
decoding (1) 1
development and progression (1) 1
diagnosis (1) 1
diagnosis, differential (1) 1
dissection (1) 1
drug dosages (1) 1
drug resistance, neoplasm - drug effects (1) 1
drug resistance, neoplasm - genetics (1) 1
drug-resistance (1) 1
edema (1) 1
endocrine therapy (1) 1
endothelial cells - pathology (1) 1
endothelial growth-factor (1) 1
endpoint determination (1) 1
enzym (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 06/2018, Volume 558, Issue 7711, pp. 605 - 609
Reprogramming of mRNA translation has a key role in cancer development and drug resistance(1). However, the molecular mechanisms that are involved in this... 
CELLS | MELANOMA | INHIBITION | TRANSFER-RNAS | KINASE | IMPROVED SURVIVAL | MUTATIONS | HUMAN CANCER | VEMURAFENIB | RIBOSOME | MULTIDISCIPLINARY SCIENCES | Phosphorylation | Humans | Melanoma, Experimental - drug therapy | Male | Uridine - genetics | RNA, Messenger - metabolism | Vemurafenib - therapeutic use | Melanoma - genetics | RNA, Transfer - genetics | Carrier Proteins - chemistry | Female | Codon - genetics | Codon - drug effects | RNA, Transfer - chemistry | Uridine - chemistry | Signal Transduction | RNA, Transfer - metabolism | RNA, Messenger - genetics | Melanoma, Experimental - pathology | Melanoma - pathology | Mice, SCID | Vemurafenib - pharmacology | Zebrafish - genetics | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Mechanistic Target of Rapamycin Complex 2 - metabolism | Drug Resistance, Neoplasm - genetics | Animals | Carrier Proteins - metabolism | Melanoma, Experimental - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Line, Tumor | Mice, Inbred NOD | Protein Biosynthesis - drug effects | Uridine - metabolism | Mice | Drug Resistance, Neoplasm - drug effects | Care and treatment | Codon | Oncology, Experimental | Melanoma | Research | Genetic translation | Cancer | Enzymes | Physiological aspects | Development and progression | Protein biosynthesis | Transfer RNA | Short term | Therapy | Transformation | Genomes | mRNA | Kinases | Proteins | Signal transduction | Translation | Cell survival | tRNA | MAP kinase | Pharmacology | Decoding | Metabolism | Gene expression | Chemical compounds | Survival | Molecular chains | 1-Phosphatidylinositol 3-kinase | Signaling | Molecular modelling | Protein synthesis | Uridine | Glycolysis | Mutation
Journal Article
by Galimberti, Viviana and Cole, Bernard F and Viale, Giuseppe and Veronesi, Paolo and Veronesi, Umberto and Veronesi, Andreas and Vicini, Elisa and Intra, Mattia and Mazzarol, Giovanni and Massarut, Samuele and Zgajnar, Janez and Taffurelli, Mario and Littlejohn, David and Knauer, Michael and Tondini, Carlo and Di Leo, Angelo and Colleoni, Marco and Regan, Meredith M and Coates, Alan S and Gelber, Richard D and Goldhirsch, Aron and Boyle, Fran and Jerusalem, Guy and Stahel, Rolf and Aebi, Stefan and Green, Michael and Karlsson, Per and Kössler, Ingrid and Láng, Istvan and Hiltbrunner, Anita and Bernhard, Jürg and Fournarakou, Stamatina and Kammler, Roswitha and Maibach, Rudolf and Rabaglio, Manuela and Ribi, Karin and Roschitzki, Heidi and Roux, Susanne and Ruepp, Barbara and Mahoney, Caitlin and Price, Karen and Blacher, Lynette and Scolese, Tara and Scott, Karolyn and Lippert, Sandra and Zielinski, Theresa and Mastropasqua, Mauro and Andrighetto, Stefania and Dell'Orto, Patrizia and Renne, Giuseppe and Pruneri, Giancarlo and Dellapasqua, Silvia and Iorfida, Monica and Cancello, Giuseppe and Montagna, Emilia and Cardillo, Anna and Peruzzotti, Giulia and Ghisini, Raffaella and Luini, Alberto and Gentilini, Oreste and Zurrida, Stefano and Curigliano, Giuseppe and Nole, Franco and Orecchia, Roberto and Leonardi, Marisa Cristina and Baratella, Paola and Chifu, Camelia and Sargenti, Manuela and Crivellari, Diana and Morassut, Sandro and Mileto, Mario and Piccoli, Erica and Magri, Marisa Donatella and Buonadonna, Angelo and Candiani, Ezio and Carbone, Antonino and Perin, Tiziana and Volpe, Rachele and Roncadin, Mario and Arcicasa, Mauro and Coran, Francesco and Lagrassa, Manuela and Recalcati, Angelo and Limonta, Maria Emanuela and Tricomi, Paolo and Fenaroli, Privato and Candiago, Elisabetta and Cattaneo, Laura and Gianatti, Alberto and Santini, Donatella and Maweja, Sylvie and Delvenne, Philippe and Rorive, Andrée and Collignon, Joëlle and Garbay, Jean-Remi and Mathieu, Marie-Christine and Galatius, Hanne and Hoffmann, Jack and Schousen, Peer and Lanng, Charlotte and ... and Int Breast Canc Study Grp Trial 23 and International Breast Cancer Study Group Trial 23-01
The Lancet Oncology, ISSN 1470-2045, 10/2018, Volume 19, Issue 10, pp. 1385 - 1393
We previously reported the 5-year results of the phase 3 IBCSG 23-01 trial comparing disease-free survival in patients with breast cancer with one or more... 
SURGERY | WOMEN | MULTICENTER | METASTASIS | ONCOLOGY | LYMPH-NODES | BIOPSY | RECURRENCE | EORTC 10981-22023 AMAROS | Care and treatment | Cancer patients | Breast cancer | Analysis | Surgery
Journal Article
Future Oncology, ISSN 1479-6694, 06/2015, Volume 11, Issue 12, pp. 1775 - 1789
The identification of additional chemotherapy agents for anthracycline-and taxane-pretreated advanced breast cancer (ABC) is an urgent medical need. Single... 
vinorelbine | capecitabine | ixabepilone | irinotecan | randomized trial | eribulin | metastatic breast cancer | gemcitabine | chemotherapy | etirinotecan pegol | MULTICENTER | RANDOMIZED-TRIALS | ETIRINOTECAN PEGOL NKTR-102 | PHASE-III TRIAL | IXABEPILONE PLUS CAPECITABINE | THERAPY | PHARMACOKINETICS | ONCOLOGY | ANTHRACYCLINE | TAXANE | VINORELBINE MONOTHERAPY
Journal Article
Case Reports in Dermatology, ISSN 1662-6567, 04/2019, Volume 11, Issue 1, pp. 101 - 107
BRAF inhibitors may present several cutaneous adverse effects, including actinic keratosis, squamous cell carcinoma, keratoacanthoma, rashes, increased... 
Case Report | Hospitals | Sarcoidosis | Dermatology | Melanoma | Skin | Metastasis | Pruritus | Mutation | Tattoos | Patients | Dabrafenib | Granuloma | Tattoo | BRAF inhibitor | Adverse drug reaction
Journal Article
Nuclear Medicine Communications, ISSN 0143-3636, 03/2011, Volume 32, Issue 3, pp. 168 - 176
OBJECTIVETo evaluate the accuracy of F-fluoride PET/computed tomography (CT) to detect bone metastases (BMs) in a breast and prostate cancer population, using... 
bone metastases | breast cancer | F-fluoride | prostate cancer | PET/computed tomography
Journal Article
Future oncology (London, England), 2015, Volume 11, Issue 12, p. 1775
The identification of additional chemotherapy agents for anthracycline- and taxane-pretreated advanced breast cancer (ABC) is an urgent medical need. Single... 
Brain Neoplasms - secondary | Antineoplastic Agents - adverse effects | Breast Neoplasms - pathology | Humans | Female | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy
Journal Article
Journal Article
Melanoma Research, ISSN 0960-8931, 12/2016, Volume 26, Issue 6, pp. 631 - 634
Increased awareness among dermatologists as well as the development of dermoscopy and sequential dermoscopy have contributed significantly toward an increase... 
atypical presentation | diagnosis | melanoma | atypical melanoma | MEDICINE, RESEARCH & EXPERIMENTAL | ONCOLOGY | MALIGNANT-MELANOMA | PRESENTATIONS | FEATURES | DERMATOLOGY | Skin Neoplasms - pathology | Diagnosis, Differential | Melanoma - diagnosis | Humans | Skin Neoplasms - diagnosis | Female | Male | Aged | Melanoma - pathology
Journal Article
Revue du Praticien, ISSN 0035-2640, 11/2007, Volume 57, Issue 17, pp. 1864 - 1870
Journal Article
La Revue du praticien, ISSN 0035-2640, 11/2007, Volume 57, Issue 17, p. 1864
Positron emission tomography (PET) has been widely used for several years for staging and response evaluation in oncology. It is time to critically review its... 
Humans | Fluorodeoxyglucose F18 | Neoplasm Recurrence, Local - diagnosis | Neoplasms - diagnosis | Positron-Emission Tomography | Radiopharmaceuticals | Patient Selection
Journal Article
Dermatology and Therapy, ISSN 2193-8210, 6/2014, Volume 4, Issue 1, pp. 131 - 135
Treatment options for melanoma in situ (MIS) include imiquimod, radiation therapy, cryotherapy, excisional and Mohs surgery. Ingenol mebutate is a new topical... 
Plastic Surgery | Topical treatment | Alternative therapy | Medicine & Public Health | Dermatology | Quality of Life Research | Internal Medicine | Oral and Maxillofacial Surgery | Melanoma treatment | In situ melanoma | Ingenol mebutate
Journal Article
Breast Cancer : Targets and Therapy, ISSN 1179-1314, 04/2014, Volume 2014, Issue default, pp. 43 - 57
Guy Jerusalem, Andree Rorive, Joelle Collignon Medical Oncology, CHU Sart Tilman Liege, Domaine Universitaire du Sart Tilman, Liege, Belgium Abstract: Many... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.